Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Genetic Technologies stock | $3.6

Own Genetic Technologies stock in just a few minutes.

Fact checked

Genetic Technologies Limited is a diagnostics & research business based in the US. Genetic Technologies shares (GENE) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Genetic Technologies

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Genetic Technologies. Find the stock by name or ticker symbol: GENE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Genetic Technologies reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.6, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Genetic Technologies, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Genetic Technologies. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Genetic Technologies share price

Use our graph to track the performance of GENE stocks over time.

Genetic Technologies shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$3.6
52-week rangeUSD$1.4083 - USD$5.78
50-day moving average USD$3.2776
200-day moving average USD$3.3959
Wall St. target priceUSD$12.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.3

Buy Genetic Technologies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Genetic Technologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genetic Technologies price performance over time

Historical closes compared with the close of $3.6 from 2020-12-31

1 week (2021-01-12) -16.86%
1 month (2020-12-18) 5.26%
3 months (2020-10-19) 1.69%
6 months (2020-07-17) -36.51%
1 year (2020-01-17) -8.63%
2 years (2019-01-18) 339.02%
3 years (2018-01-19) 106.90%
5 years (2016-01-19) 93.55%

Genetic Technologies financials

Gross profit TTM USD$-241,647
Return on assets TTM -48.8%
Return on equity TTM -82.49%
Profit margin 0%
Book value $0.15
Market capitalisation USD$44.2 million

TTM: trailing 12 months

Shorting Genetic Technologies shares

There are currently 1.0 million Genetic Technologies shares held short by investors – that's known as Genetic Technologies's "short interest". This figure is 75.9% up from 595,469 last month.

There are a few different ways that this level of interest in shorting Genetic Technologies shares can be evaluated.

Genetic Technologies's "short interest ratio" (SIR)

Genetic Technologies's "short interest ratio" (SIR) is the quantity of Genetic Technologies shares currently shorted divided by the average quantity of Genetic Technologies shares traded daily (recently around 1.9 million). Genetic Technologies's SIR currently stands at 0.55. In other words for every 100,000 Genetic Technologies shares traded daily on the market, roughly 550 shares are currently held short.

However Genetic Technologies's short interest can also be evaluated against the total number of Genetic Technologies shares, or, against the total number of tradable Genetic Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genetic Technologies's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Genetic Technologies shares in existence, roughly 80 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Genetic Technologies shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genetic Technologies.

Find out more about how you can short Genetic Technologies stock.

Genetic Technologies share dividends

We're not expecting Genetic Technologies to pay a dividend over the next 12 months.

Have Genetic Technologies's shares ever split?

Genetic Technologies's shares were split on a 1:4 basis on 15 August 2019. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genetic Technologies shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Genetic Technologies shares which in turn could have impacted Genetic Technologies's share price.

Genetic Technologies share price volatility

Over the last 12 months, Genetic Technologies's shares have ranged in value from as little as $1.4083 up to $5.78. A popular way to gauge a stock's volatility is its "beta".

GENE.US volatility(beta: 1.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genetic Technologies's is 1.0098. This would suggest that Genetic Technologies's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Genetic Technologies overview

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site